The recent development in the field of ranolazine

Molecular Formula:C24H33N3O4
Molecular Weight: 427.54
Density:1.174 g/cm3
Boiling Point:624.1 C at 760 mmHg
Flash Point:331.2 C
Appearance: white solid
CAS Registry Number:95635-55-5
Usage: Anti-ischemic agent which modulates myocardial metabolism.

Ranolazine is used alone or with other medications to treat ongoing angina (chest pain or pressure that is felt when the heart does not get enough oxygen). Ranolazine is in a class of medications called anti-anginals. The exact way that ranolazine works is not known at this time.

Ranolazine(CAS NO: 95635-55-5) is a medication that belongs to the drug class known as cardiovascular agents. Ranexa is prescribed for the treatment of chronic angina. Common side effects of Ranexa include dizziness, nausea, constipation, headache, swelling in hands, ankles, or feet, slow, fast, or irregular heartbeats, tremors, blood in the urine and shortness of breath.

This is the recent development in the field of ranolazine. This study was done in 6560 post-ACS NSTEMI patients followed up for one year. Although ranolazine did not show significant benefit in the study's primary endpoints of cardiovascular death, myocardial infarction, or recurrent ischemia; it exhibited a potential benefit in arrhythmia.

Earlier, ranolazine increasing QT interval (about 2 to 6 ms) was of concern, which has a theoretical risk of causing arrhythmia. Findings of MERLIN TIMI 36 should mitigate this concern. However, studies specifically designed to evaluate the potential role of ranolazine as an antiarrhythmic agent are warranted.

Based on encouraging safety data shown in MERLIN TIMI 36 trial, CV Therapeutics has applied to the US FDA for first-line angina indication. It has also applied to the U.S. Food and Drug Administration (FDA) for two more indications, such as HbA1c reduction in coronary artery disease patients with diabetes and antiarrhythmic benefits. Based on initial evaluation of data presented, the FDA has accepted the application and has set the action date as 27 July 2008.

Among patients with ACS, ranolazine, an inhibitor of late INa, has antiarrhythmic effects as assessed by Holter monitoring. In particular, patients treated with ranolazine had fewer episodes of VT > 8 beats, SVT, and ventricular pauses > 3 seconds. Ranolazine was associated with a 37% reduction in risk of VT lasting >= 8 beats. Reduction in VT >= 8 beats was significant and consistent in high-risk subgroups based on ejection fraction, corrected QT interval, TIMI risk score, history of heart failure, and the presence or absence of ischemia on ECG.

Want to learn more information about Ranolazine, you can access the guidechem.com. Guidechem chemical B2B network provides information on china and global chemical market quotation and relative chemical Information.